According to Zaina et al., treatment with SGLT-2 inhibitors could be considered for T2DM in patients with acromegaly in the following cases: in patients with previously diagnosed T2DM and controlled acromegaly after surgery, in patients with T2DM and controlled acromegaly treated with long-acting somatostatin analogs or pegvisomant, and patients treated with long-acting pasireotide with worsening hyperglycemia or new-onset diabetes. This evidence concerns the gene SLC5A2 and acromegaly.